| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
EXTENDED REPORT |
1 Clinical Research, Denver Arthritis Clinic PC, Denver, CO, USA
2 Department of Rheumatology, Charité Humboldt University, Berlin, Germany
3 Immunology, Abbott Laboratories, Abbott Park, IL, USA
4 Immunoscience Europe, Abbott GmbH & Co. KG, Ludwigshafen, Germany
5 Postmarketing Safety Evaluation, Abbott Laboratories, Abbott Park, IL, USA
6 Immunology, Abbott Laboratories, Parsippany, NJ, USA
Correspondence to:
Correspondence to:
Dr Michael H Schiff
Clinical Research, Denver Arthritis Clinic, 200 Spruce Street, Suite 100, Denver, CO 80230, USA; crendon{at}denverarthritisclinic.com
Objective: To assess the safety of adalimumab in global clinical trials and postmarketing surveillance among patients with rheumatoid arthritis (RA).
Methods: Safety data for adalimumab treated patients from randomised controlled trials, open label extensions, and two phase IIIb open label trials were analysed. In addition, postmarketing spontaneous reports of adverse events in the United States were collected following Food and Drug Administration approval of adalimumab on 31 December 2002.
Results: As of 15 April 2005, the RA clinical trial safety database analysed covered 10 050 patients, representing 12 506 patient-years (PYs) of adalimumab exposure. The rate of serious infections, 5.1/100 PYs, was comparable to that reported on 31 August 2002 (4.9/100 PYs), and to published reports of RA populations naive to anti-tumour necrosis factor (TNF) therapy. Following implementation of tuberculosis (TB) screening in clinical trials, the rate of TB decreased. There were 34 cases of TB as of this analysis (0.27/100 PYs). The standardised incidence ratio for lymphoma was 3.19 (95% CI 1.78 to 5.26), consistent with the observed increased incidence in the general RA population. As of 30 June 2005, there were an estimated 78 522 PYs of exposure to adalimumab in the US postmarketing period. Seventeen TB cases were spontaneously reported (0.02/100 PYs) from the US. Rates of other postmarketing events of interest, such as congestive heart failure, systemic lupus erythematosus, opportunistic infections, blood dyscrasias, lymphomas, and demyelinating disease, support observations from clinical trials.
Conclusion: Analyses of these data demonstrate that long term adalimumab treatment is generally safe and well tolerated in patients with RA.
Abbreviations: AE, adverse event; CDC, Centers for Disease Control; CHF, congestive heart failure; DMARD, disease modifying antirheumatic drug; E/100 PYs, events per 100 patient-years; FDA, Food and Drug Administration; LTB, latent TB; MTX, methotrexate; OLE, open label extension trial; PY, patient-year; RA, rheumatoid arthritis; RCT, randomised controlled trial; SAE, serious adverse event; SEER, Surveillance, Epidemiology and End Results; SIR, standardised incidence ratio; SLE, systemic lupus erythematosus; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test
Keywords: adalimumab; postmarketing surveillance; rheumatoid arthritis; safety; tumour necrosis factor antagonists
This article has been cited by other articles:
|
|
 |
|
  J. Hinojosa, J. Borras-Blasco, N. Maroto, J D. Rosique-Robles, R. Alos, and M. E. Castera Severe Myalgia Associated with Adalimumab Treatment in a Patient with Crohn's Disease Ann. Pharmacother., July 1, 2008; 42(7): 1130 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J Sanborn and on behalf of the CLASSIC-II study authors Author's reply Gut, April 1, 2008; 57(4): 559 - 560. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Mittendorf, B. Dietz, R. Sterz, M. A. Cifaldi, H. Kupper, and J.-M. von der Schulenburg Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective Rheumatology, February 1, 2008; 47(2): 188 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Donahue, G. Gartlehner, D. E. Jonas, L. J. Lux, P. Thieda, B. L. Jonas, R. A. Hansen, L. C. Morgan, and K. N. Lohr Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis Ann Intern Med, January 15, 2008; 148(2): 124 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii2 - iii22. [Full Text] [PDF]
|
|
|
|
|
|
W. J. Sandborn, P. Rutgeerts, R. Enns, S. B. Hanauer, J.-F. Colombel, R. Panaccione, G. D'Haens, J. Li, M. R. Rosenfeld, J. D. Kent, et al. Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab: A Randomized Trial Ann Intern Med, June 19, 2007; 146(12): 829 - 838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R Burmester, X. Mariette, C. Montecucco, I. Monteagudo-Saez, M. Malaise, A. G Tzioufas, J. W J Bijlsma, K. Unnebrink, S. Kary, H. Kupper, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial Ann Rheum Dis, June 1, 2007; 66(6): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pucino Jr., P. T. Harbus, and R. Goldbach-Mansky Use of biologics in rheumatoid arthritis: Where are we going? Am. J. Health Syst. Pharm., September 15, 2006; 63(18 Suppl 4): S19 - S41. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
